{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-022023","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2025-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.532725+00:00","generated_at":"2026-05-19T15:08:33.833270+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Insmed TPIP Phase 2b in PAH meets primary endpoint with 35% PVR reduction (p<0.001)","bullets":["Placebo-adjusted PVR reduction 35% (p<0.001); 6MWD improvement 35.5 m (p=0.003); NT-proBNP reduction 60% (p<0.001).","Once-daily TPIP well tolerated; 75% of patients titrated to max dose 640 µg; 90% completed study.","Insmed to engage FDA for Phase 3; PH-ILD Phase 3 by end 2025; PAH Phase 3 early 2026.","Common TEAEs: cough 40.6%, headache 31.9%, fatigue 10.1%; no deaths in study.","95% of completers enrolled in open-label extension (1,280 µg max dose allowed)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-022023","json":"https://secwatch.observer/filing/0001140361-25-022023.json","markdown":"https://secwatch.observer/filing/0001140361-25-022023.md","text":"https://secwatch.observer/filing/0001140361-25-022023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125022023/0001140361-25-022023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125022023/ef20050418_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T15:08:33.833270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}